CMV-Specific CAR T Cells for Durable HIV Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapy (ART) for HIV is ineffective in eliminating the virus, requiring lifelong treatment, and HIV-infected individuals develop mechanisms to evade T cell-mediated immune responses, necessitating a new approach for long-lasting control of HIV infection.
Innovation Solution
Utilizing chimeric antigen receptor (CAR) T cell therapy with CMV-specific T cells redirected to kill HIV-infected cells, incorporating CARs with specificities for multiple HIV gp120 epitopes, and administering these cells before, during, or after ART cessation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiretroviral therapy (ART) is used to control HIV replication, then HIV replication is dramatically reduced, but the virus is not eliminated and lifelong treatment is required
Solution Approach 1:
The patent uses CAR T cells as an intermediary immune mechanism to eliminate HIV-infected cells. These engineered T cells express chimeric antigen receptors that specifically recognize HIV antigens (such as gp120 or Tat) and mediate targeted killing of infected cells, acting as a bridge between the immune system and viral elimination without requiring continuous ART
Solution Approach 2:
The CAR T cells are designed to be self-sustaining and self-renewing within the patient's body. Once infused, these cells can persist long-term, self-proliferate, and continuously provide antiviral immunity against HIV, eliminating the need for ongoing external treatment intervention
2Reliability
If T cell-mediated immune response is used to fight HIV, then immune control is achieved, but HIV evades through various mechanisms leading to loss of T cell function
Solution Approach 1:
The patent fundamentally changes the recognition parameters of T cells by replacing native T cell receptors with engineered chimeric antigen receptors (CARs). These CARs recognize conserved HIV antigens that are less susceptible to viral mutation and escape, thereby overcoming the evasion mechanisms that limit natural T cell responses
Solution Approach 2:
The CAR structure itself is a composite molecular construct combining an antigen-binding single-chain variable fragment (scFv) with T cell signaling domains (CD3ζ, CD28, or 4-1BB). This composite design integrates antigen recognition capabilities with potent T cell activation and survival signaling, creating a more effective immune effector than native T cells alone
3Reliability
If CAR T cells are used to kill HIV-infected cells, then HIV-infected cells are reduced or eradicated, but viral escape may emerge
Solution Approach 1:
The patent employs multiple CAR T cell products targeting different HIV antigens (e.g., gp120, Tat, other conserved epitopes) in combination or sequence. This segmentation of the antiviral response across multiple targets makes it harder for the virus to develop escape mutations, as it would need to simultaneously evade multiple distinct antigenic targets
Solution Approach 2:
The CAR T cells are engineered with predetermined specificity against conserved HIV antigens that are essential for viral function and less prone to mutation. This preliminary design choice anticipates and prevents viral escape by targeting regions of the virus that cannot easily change without losing fitness
Data Source
AI summary
Methods of treatment for HIV employing T cells expressing both a chimeric antigen receptors targeted to HIV and a CMV-specific T cell receptor.